Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Adaptimmune Therapeutics Plc (ADAP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Adaptimmune Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.210 +0.020    +1.68%
01/05 - Closed. Currency in USD ( Disclaimer )
After Hours
1.220
+0.010
+0.826%
0:50:00 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 911,080
  • Bid/Ask: 1.180 / 1.230
  • Day's Range: 1.160 - 1.250
Adaptimmune Therapeutics 1.210 +0.020 +1.68%

Adaptimmune Therapeutics Plc Company Profile

 
Get an in-depth profile of Adaptimmune Therapeutics Plc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

449

Equity Type

ADR

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Contact Information

Address 60 Jubilee Avenue Milton Park
Abingdon, OX14 4RX
United Kingdom
Phone 44 12 3543 0000
Fax 44 12 3543 0001

Top Executives

Name Age Since Title
Lawrence M. Alleva 71 2015 Independent Non-Executive Director
Adrian G. Rawcliffe 49 2015 CEO, Principal Accounting Officer & Director
David M. Mott 56 2015 Independent Chairman of the Board of Directors
Wolf H. Fridman - - Member of the Scientific Advisory Board
Ali Behbahani 47 2015 Independent Non-Executive Director
Kristen M. Hege 60 2023 Independent Non-Executive Director
Andy Sewell - - Member of the Scientific Advisory Board
Stephan A. Grupp - - Member of the Scientific Advisory Board
Mario Sznol - - Member of the Scientific Advisory Board
Wolf Herve Fridman - - Member of the Scientific Advisory Board
Thomas Gajewski - - Member of the Scientific Advisory Board
Michael Dustin - - Member of the Scientific Advisory Board
Malcolm K. Brenner 71 - Member of the Scientific Advisory Board
Priti Hegde 52 2023 Independent Non-Executive Director
Garry E. Menzel 60 2023 Independent Non-Executive Director
Andrew R. Allen 58 2023 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ADAP Comments

Write your thoughts about Adaptimmune Therapeutics Plc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email